Compare Bristol-Myers Squibb Co (BMY) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vanguard Total World Stock Index Fund ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.74 (market cap $132.45B), while Vanguard Total World Stock Index Fund ETF trades at $161.34. The key difference: Bristol-Myers Squibb Co pays a 3.89% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals.
| BMY | VT | |
|---|---|---|
Market Cap | $132.45B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $65.89 | $161.30 |
52-Week Low | $42.60 | $132.19 |
Enterprise Value | $166.44B | — |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vanguard Total World Stock ETF (VT) trades at $161.3, up 0.86% on the day, with a bullish technical signal driven by moving averages. The ETF offers broad global diversification across over 10,000 stocks with a low 0.06% expense ratio. Recent institutional activity shows mixed positioning adjustments, while news highlights its role in global portfolios amid trade policy uncertainty.
VT presents a long-term diversification opportunity with low-cost global equity exposure, though near-term risks include trade war volatility and seasonal choppiness. The neutral oscillator signals and high short-term RSI suggest potential consolidation, but strong institutional interest supports its core holding appeal for risk-conscious investors seeking worldwide market access.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
